Value of tumor size as a prognostic factor in metastatic colorectal cancer patients after chemotherapy: a population-based study

Future Oncol. 2019 May;15(15):1745-1758. doi: 10.2217/fon-2018-0785. Epub 2019 Apr 30.

Abstract

Aim: To evaluate the relationship between tumor size and survival in metastatic colorectal cancer (mCRC) patients who received chemotherapy. Materials & methods: SEER database was accessed for eligible patients. Multivariate Cox regression analysis was performed to compare the effect of tumor size on overall survival (OS) and CRC-specific survival (CCSS). Results: Tumor size ≥5 cm was an independent risk factor for OS and CCSS in mCRC patients treated with chemotherapy. Tumor size <5 cm did not show a survival advantage in patients whose primary tumor site was rectosigmoid junction, while tumor size ≥5 cm was associated with poor OS and CCSS in left-and right-sided colorectal cancer. Conclusion: Tumor size ≥5 cm was associated with poor prognosis after receiving chemotherapy treatment and a risk factor for survival of mCRC.

Keywords: chemotherapy; metastatic colorectal cancer; tumor size.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Colorectal Neoplasms / drug therapy
  • Colorectal Neoplasms / epidemiology
  • Colorectal Neoplasms / mortality*
  • Colorectal Neoplasms / pathology*
  • Female
  • Humans
  • Incidence
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Population Surveillance
  • Prognosis
  • Proportional Hazards Models
  • SEER Program
  • Treatment Outcome
  • Tumor Burden